Solstice Biologics is developing a delivery mechanism intended to allow RNA therapeutics to penetrate tissues. The company was founded in 2013 and drew public attention early due to a violent incident involving founders. Its science has attracted investor interest despite the rocky start. Solstice raised an $18 million Series A since founding, backed largely by venBio and Aeris Capital AG. A regulatory filing shows it recently raised $4 million from two investors, though the company has been quiet about how it will use the new funds. The firm has undergone management changes: Lou Tartaglia joined in June 2014 but is listed as “temporarily retired” as of this past June, and Dr. Corey Goodman has assumed the CEO role. Solstice Biologics is focused on solving the problem of targeting and delivering nucleic acid therapeutics. The company is developing proprietary technology that enables short double-stranded RNAi and microRNA molecules to cross cell membranes. It has an exclusive license to University of California, San Diego intellectual property covering technology that enables RNA molecules to cross membranes of multiple cell types. Founders include Steven Dowdy, Ph.D., and Curt Bradshaw, Ph.D., who heads its research laboratories in San Diego. The company is building programs around its delivery platform to enable nucleic acid therapeutics across multiple cell types. Financially, Solstice completed an $18M Series A financing led by venBio with participation from Aeris Capital AG.

Total raised

$22M

Funding rounds

2

Latest round

Equity

Latest activity

Dec 2015